CD8(+) T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer

Nishii, K; Ohashi, K; Tomida, S; Nakasuka, T; Hirabae, A; Okawa, S; Nishimura, J; Higo, H; Watanabe, H; Kano, H; Ando, C; Makimoto, G; Ninomiya, K; Kato, Y; Kubo, T; Ichihara, E; Hotta, K; Tabata, M; Toyooka, S; Udono, H; Maeda, Y; Kiura, K

Ohashi, K (通讯作者)，Okayama Univ Hosp, Dept Resp Med, 2-5-1 Shikata Cho,Kita Ku, Okayama 7008558, Japan.

CANCER IMMUNOLOGY RESEARCH, 2022; 10 (9): 1111

Abstract

Epidermal growth factor receptor (EGFR) is the most frequently mutated driver oncogene in nonsmoking-related, non-small cell lung cancer (NSCLC). EGFR......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索